This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial

Wednesday, March 26, 2014

Submitted by


Source Name: Journal of Thoracic and Cardiovascular Surgery


J Puskas, M Gerdisch, D Nichols, R Quinn, C Anderson, B Rhenman, L Fermin, M McGrath, B Kong, C Hughes, G Sethi, M Wait, T Martin, A Graeve
The PROACT trial is evaluating the clinical utility and safety of less aggressive anticoagulation schemes after bileaflet AVR. This arm of the trial compared low dose (INR 1.5-2.0) to standard dose (INR 2.0-3.0)warfarin. At an average follow-up of nearly 4 years, the low dose group experienced significantly fewer bleeding complications but had similar rates of neurologic events and all-cause mortality.

Add comment

Log in or register to post comments